US Bancorp’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

US Bancorp’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-100	Closed	-$1K	–	3848
2019 Q4	$1K	Hold	100	–	–	﹤0.01%	3612
2019 Q3	$1K	Hold	100	–	–	﹤0.01%	3535
2019 Q2	$2K	Hold	100	–	–	﹤0.01%	3498
2019 Q1	$3K	Hold	100	–	–	﹤0.01%	3379
2018 Q4	$3K	Hold	100	–	–	﹤0.01%	3356
2018 Q3	$6K	Hold	100	–	–	﹤0.01%	3287
2018 Q2	$7K	Hold	100	–	–	﹤0.01%	3253
2018 Q1	$7K	Hold	100	–	–	﹤0.01%	3261
2017 Q4	$8K	Sell	100 -11	-10%	-$1.08K	﹤0.01%	3215
2017 Q3	$13K	Buy	111 +11	+11%	+$1.16K	﹤0.01%	3025
2017 Q2	$12K	Buy	+100	New	+$12.4K	﹤0.01%	3027
2015 Q4	–	Sell	-280	Closed	-$41K	–	3730
2015 Q3	$41K	Hold	280	–	–	﹤0.01%	2556
2015 Q2	$60K	Sell	280 -5	-2%	-$1.23K	﹤0.01%	2445
2015 Q1	$66K	Buy	+285	New	+$68.9K	﹤0.01%	2401

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

US Bancorp's BLCM Position: Q1 2020 in Review

US Bancorp sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2020, closing a stake of 100 shares — an estimated $1K sold.

US Bancorp first reported a position in BLCM in Q1 2015 and held it in 14 quarters. The position peaked at $66K in Q1 2015. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2020.

US Bancorp reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
US Bancorp sold 100 Bellicum Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1K.
US Bancorp first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 14 quarters.
US Bancorp's Bellicum Pharmaceuticals, Inc. position peaked at $66K in Q1 2015.
29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2020.

Based on US Bancorp's 13F filing for Q1 2020, filed 13 May 2020.